Evaluation of the WATCHMAN Left Atrial Appendage (LAA) Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 407 participants.

Also called NCT01182441

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 407 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01182441
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01182441. Randomized; no masking; primary purpose treatment. Start 2010-11 (actual); primary completion 2013-01 (actual). Results posted on 2018-07-26.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Evaluation of the WATCHMAN Left Atrial Appendage (LAA) Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy
Acronym
PREVAIL
Condition
Stroke
Intervention (Device)
WATCHMAN Device
Intervention (Drug)
Warfarin
Lead sponsor
Boston Scientific Corporation (class: industry)

Record details

Record id
cardio:ct-nct01182441
Content hash
32f1b7dec340c07ae65c80044f3a60fbf4edf7b82944ef19847520295c8c5062